Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

SEATTLE, March 26, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data from the multiple-ascending-dose (MAD) portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. With these data and the previously announced successful single-ascending-dose portion of this clinical trial, Omeros is advancing OMS824 toward a Phase 2 clinical program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.

The OMS824 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study. The trial enrolled 64 healthy male subjects; 40 subjects received a single dose and 24 subjects received daily dosing for 7 to 10 days. OMS824 was well tolerated by all subjects, and the only apparent drug-related adverse event was mild somnolence at the highest dose evaluated. No subject had extrapyramidal symptoms (e.g., involuntary muscle movements), which are associated with marketed antipsychotic medications and have been seen with other companies' PDE10 inhibitors at levels of approximately 50-percent engagement of the PDE10 enzyme in the brain. A radiotracer imaging study is underway to confirm the target engagement of OMS824 in human brains.

The study results showed that the pharmacokinetic parameters (Cmax and AUC) increased linearly with the dose and that OMS824 had a long half-life that is consistent with once daily dosing. OMS824 was detected in the cerebrospinal fluid at the expected concentration relative to that in the blood. The drug concentration in the cerebrospinal fluid is predicted to achieve near-complete inhibition of the PDE10 target in the brain. These resul
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist Kevin ... recently traveled to Boston, MA ... the 2015 Heart Rhythm Society conference. These scientific ... focus on the ideas, people and technology that ... is a hybrid, minimally invasive cardiac operation that ...
(Date:5/22/2015)... 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a ... and regeneration, today announced that J.J. Finkelstein , ... a corporate overview at two upcoming investor conferences. ... 4 th Annual Microcap Conference on Thursday May ... at 11:00 am EDT.  A webcast will be ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... Feb. 1, 2011 Reportlinker.com announces that a new ... Personalized Medicine - scientific & commercial ... Summary The aim of ... right drug to the right patient and, in some ...
... of Dermatology, Laser and Cosmetics is now offering Alma Lasers ... Boerne area to treat superficial vascular and pigmented irregularities and ... add this new service for our patients," said Dr. Ghohestani, ... a long time provider of aesthetic medicine, we wanted to ...
Cached Medicine Technology:Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects 2Reportlinker Adds Personalized Medicine - Scientific & Commercial Aspects 3San Antonio's Texas Institute of Dermatology, Laser and Cosmetics Adds Alma Lasers Harmony XL Cosmetic Laser to Offer Advanced Rejuvenation Treatments to Patients 2
(Date:5/24/2015)... Geneva, WI (PRWEB) May 24, 2015 ... Mercy Health System CEO - ... principal and honored at the fourth ... held April 15 at Geneva National ... (by school): ,     -Badger High School, ...
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at ... the 2015 Congress of Future Medical Leaders in Boston, ... of “America’s highest achieving high school students.” , “I’m ... new goals and learn better study habits,” said Omar. ... which we can ask the surgeons questions.” , The ...
Breaking Medicine News(10 mins):Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2
... French . , Toronto (March 16, 2011) ... received $16 million in funding. The studies, co-funded by the ... Agency (CSA), were announced today at the University of Toronto ... Jane Aubin, Scientific Director of the Canadian Institutes of Health ...
... WEDNESDAY, March 16 (HealthDay News) -- The brain structure of ... a new study. Some of these differences may be ... are likely to be present from birth, said the team ... in the study of phonetics and are able to distinguish ...
... A research article co-authored by Brenna Anderson, MD, director ... Maternal-Fetal Medicine at Women & Infants Hospital of Rhode ... of the American Journal of Reproductive Immunology . ... on the human immunodeficiency virus (HIV) that took place ...
... HealthDay Reporter , WEDNESDAY, March 16 (HealthDay News) ... their health benefits during the recession often had no way ... at risk of financial ruin, according to a new report ... the recession catapulted 9 million more Americans -- or ...
... New York, NY, March 16, 2011An estimated nine million ... a job that was lostbecame uninsured in the last two ... Survey, released today. The survey paints a bleak picture for ... they or their spouse lost a job in the past ...
... HealthDay Reporter , TUESDAY, March 15 (HealthDay News) -- ... blood levels of phosphorous, calcium and parathyroid hormone, to assess ... of research stretching back more than 60 years casts doubt ... found little evidence to support the notion that these "biomarkers" ...
Cached Medicine News:Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Brains of Phonetics Experts Differ From Those of General Public 2Health News:HIV research included in journal 2Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 2Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 3Health News:Report: Unemployment Adds 9 Million Uninsured in U.S. 4Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 2Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 3Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 4Health News:New health insurance survey: 9 million adults joined ranks of uninsured due to job loss in 2010 5Health News:Study Questions Tests Used to Spot Heart Risks in Kidney Patients 2Health News:Study Questions Tests Used to Spot Heart Risks in Kidney Patients 3
SunGlide™ Stylette - Blue Neonatal. Use in 2.0 to 3.5mm tubes. 25/box....
Hollow Copper Tube with Suction Port 16.5....
Surgical Stainless Steel Adult 16.5....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Medicine Products: